Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
March 10 2023 - 3:37PM
Business Wire
Omeros Corporation (Nasdaq: OMER), in response to investor
inquiries, is confirming that it has no banking or other financial
relationship with Silicon Valley Bank.
Omeros previously maintained a line of credit with Silicon
Valley Bank, which the company allowed to expire in August 2022.
Omeros does not have any assets on deposit with Silicon Valley
Bank, nor does the company maintain any other financial
relationship with the bank or its affiliated entities.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing in clinical programs for paroxysmal nocturnal
hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and one or
more related indications. For more information about Omeros and its
programs, visit www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230310005382/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024